Department of Surgery, Division of Urology, Lapland Central Hospital, Rovaniemi, Finland.
Department of Urology, Oulu University, Oulu, Finland.
BMJ Case Rep. 2022 May 17;15(5):e246653. doi: 10.1136/bcr-2021-246653.
According to the current understanding, radiotherapy can enhance the effectiveness of cancer immunotherapy due to radiation-induced release of tumour-associated antigens. Here, we present a case with a metastatic urothelial carcinoma who received nivolumab and palliative radiotherapy to a residual tumour in the vagina and to a large metastatic visceral lymph node. The treatment resulted in a rapid and virtually complete response for the time being in all metastases and in the large parailiac tumour mass. Follow up continues. The presented case demonstrates that the combinatory treatment with radiotherapy and immunotherapy can result in an exceptional response for the benefit of the patient with urothelial cancer. To our knowledge, this is one of the largest metastatic masses to disappear with a combination of immuno-oncologic (nivolumab) and radiation therapies.
根据目前的认识，放疗可以通过放射诱导肿瘤相关抗原的释放来提高癌症免疫治疗的效果。在这里，我们报告了 1 例转移性尿路上皮癌患者，该患者接受了纳武单抗和姑息性放疗，以治疗阴道内残留肿瘤和大的转移性内脏淋巴结。治疗后，所有转移灶和巨大的腹膜旁肿瘤均暂时迅速且几乎完全缓解。随访仍在继续。该病例表明，放疗和免疫治疗的联合治疗可能会为患者带来获益，产生显著的抗肿瘤反应。据我们所知，这是免疫肿瘤学（纳武单抗）联合放射治疗使最大的转移性肿瘤消退的病例之一。
